Determination of whether the biological variation of fasting lipids differs between simvastatin and atorvastatin therapy in patients with type 2 diabetes: implications for treating to target

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN73479504

Enrollment

Registered

2007-09-03

Start date

2005-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes, hypercholestrolemia Nutritional, Metabolic, Endocrine Type 2 diabetes, hypercholestrolemia

Interventions

All participants were on stable doses of medications (i.e. either atorvastatin 10 mg or simvastatin 40 mg) for at least 3 months. Biological variations of Total Cholesterol (TC), High-Density Lipopro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes on either atorvastatin 10 mg or simvastatin 40 mg.

Exclusion criteria

Exclusion criteria: 1. Not on concomitant fibrate or additional lipid lowering therapy 2. Inadequately treated hypothyroidism 3. Nephrotic syndrome

Design outcomes

Primary

Measure	Time frame
Biological variability of TC and LDL-C (see Interventions for timepoints of measurement).	—

Secondary

Measure	Time frame
Biological variation of triglycerides and hsCRP (see Interventions for timepoints of measurement).	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026